Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

John S. Macdonald; Jacqueline K. Benedetti; Manuel Modiano; David S. Alberts

doi:10.1023/A:1005941603420

Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

John S. Macdonald, Jacqueline K. Benedetti, Manuel Modiano, David S. Alberts

Research output: Contribution to journal › Article

17 Scopus citations

Abstract

The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m²/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

Original language	English (US)
Pages (from-to)	357-359
Number of pages	3
Journal	Investigational New Drugs
Volume	15
Issue number	4
DOIs	https://doi.org/10.1023/A:1005941603420
State	Published - Dec 1 1997
Externally published	Yes

Keywords

Colorectal cancer
Topoisomerase-1 inhibitor
Topotecan

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1005941603420

Fingerprint Dive into the research topics of 'Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)'. Together they form a unique fingerprint.

Cite this

Macdonald, J. S., Benedetti, J. K., Modiano, M., & Alberts, D. S. (1997). Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Investigational New Drugs, 15(4), 357-359. https://doi.org/10.1023/A:1005941603420

@article{6f5625fb82f64eccb341116ad83f7698,

title = "Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)",

abstract = "The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.",

keywords = "Colorectal cancer, Topoisomerase-1 inhibitor, Topotecan",

author = "Macdonald, {John S.} and Benedetti, {Jacqueline K.} and Manuel Modiano and Alberts, {David S.}",

year = "1997",

month = dec,

day = "1",

doi = "10.1023/A:1005941603420",

language = "English (US)",

volume = "15",

pages = "357--359",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

AU - Macdonald, John S.

AU - Benedetti, Jacqueline K.

AU - Modiano, Manuel

AU - Alberts, David S.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

AB - The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

KW - Colorectal cancer

KW - Topoisomerase-1 inhibitor

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0031424630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031424630&partnerID=8YFLogxK

U2 - 10.1023/A:1005941603420

DO - 10.1023/A:1005941603420

M3 - Article

C2 - 9547679

AN - SCOPUS:0031424630

VL - 15

SP - 357

EP - 359

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -